Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Archemix, which develops and commercializes aptamer therapeutics for rare hematological diseases, has announced that ARC1779 has received orphan drug designation from the European Commission.
Subscribe to our email newsletter
Archemix’s ARC1779 is currently in Phase II clinical development with a clinical trial designed to assess the safety, pharmacokinetics and pharmacodynamic effects of ARC1779 in approximately 28 patients with vWF-mediated platelet function disorders, including acute thrombotic thrombocytopenic purpura (TTP).
Archemix expects this trial to conclude in third quarter of 2008. ARC1779 has also received orphan drug designation from the FDA in April 2008.
Errol DeSouza, president and CEO of Archemix, said: “The designation of ARC1779 as an orphan drug by both the European Commission and FDA underscores the importance of developing effective treatments for patients with TTP.”